Targeting molecular alterations as an effective treatment for
isocitrate dehydrogenase-wildtype
glioblastoma (GBM) patients has not yet been established.
Sterol-O-Acyl
Transferase 1 (SOAT1), a key
enzyme in the conversion of endoplasmic reticulum
cholesterol to
esters for storage in lipid droplets (LD), serves as a target for the orphan drug
mitotane to treat
adrenocortical carcinoma. Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM and IDH-mutant
astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in these
tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP, Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as
Oil Red O staining. To a small extent SOAT1 was expressed by
tumor cells in both
tumor entities. In contrast, strong expression was observed in
glioma-associated macrophages. Triple immunofluorescence labeling revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively. Furthermore, a notable difference in the amount of LD between GBM and HGA was observed. Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and invasiveness. In addition, the high expression in cells related to
neuroinflammation could be beneficial for a concomitant suppression of protumoral microglia/macrophages.